Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer.

IF 2.5 4区 医学 Q3 ONCOLOGY
Oncology Letters Pub Date : 2024-10-22 eCollection Date: 2025-01-01 DOI:10.3892/ol.2024.14766
Hirokatsu Hayashi, Itaru Yasufuku, Yuta Sato, Seito Fujibayashi, Wakana Chikaishi, Masahide Endo, Takeshi Horaguchi, Ryoma Yokoi, Keita Matsumoto, Masashi Kuno, Yuki Sengoku, Masahiro Fukada, Ryuichi Asai, Jesse Yu Tajima, Akitaka Makiyama, Shigeru Kiyama, Yoshihiro Tanaka, Katsutoshi Murase, Takuma Ishihara, Nobuhisa Matsuhashi
{"title":"Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer.","authors":"Hirokatsu Hayashi, Itaru Yasufuku, Yuta Sato, Seito Fujibayashi, Wakana Chikaishi, Masahide Endo, Takeshi Horaguchi, Ryoma Yokoi, Keita Matsumoto, Masashi Kuno, Yuki Sengoku, Masahiro Fukada, Ryuichi Asai, Jesse Yu Tajima, Akitaka Makiyama, Shigeru Kiyama, Yoshihiro Tanaka, Katsutoshi Murase, Takuma Ishihara, Nobuhisa Matsuhashi","doi":"10.3892/ol.2024.14766","DOIUrl":null,"url":null,"abstract":"<p><p>Studies have associated neutrophil-to-lymphocyte ratio (NLR) with overall survival (OS) and progression-free survival (PFS) in patients with gastric cancer (GC). The present study aimed to examine the relationship between dynamic changes in NLR during treatment and disease progression in patients with unresectable or recurrent GC treated with nivolumab monotherapy as a third-line or later regimen. Patients treated with nivolumab as a third-line or later therapy for unresectable or recurrent GC at Gifu University Hospital (Gifu, Japan) from April 2017 to December 2021 were included. Pretreatment data and those obtained every 2 weeks after the treatment commenced were evaluated. The association between all NLR values and disease progression for each patient was evaluated using a time-dependent Cox proportional hazards model and restricted cubic spline (RCS) curves. The study included 44 patients (23 men and 21 women). The response and disease control rates were 6.8 and 27.3%, respectively. The median PFS and OS of all patients were 1.84 months [95% confidence interval (CI), 1.32-2.14] and 5.93 months (95% CI, 3.75-10.75), respectively. The risk for progressive disease (PD) increased with higher NLR (hazard ratio, 2.25; 95% CI, 1.3-3.87). The RCS curves also indicated that the higher the NLR, the higher the risk for PD, especially if the NLR value was <3.0. NLR during treatment could predict the risk of PD, suggesting that NLR could be integrated with tumor markers, computed tomographic images and other modalities to enable treatment selection without delay.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526420/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ol.2024.14766","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Studies have associated neutrophil-to-lymphocyte ratio (NLR) with overall survival (OS) and progression-free survival (PFS) in patients with gastric cancer (GC). The present study aimed to examine the relationship between dynamic changes in NLR during treatment and disease progression in patients with unresectable or recurrent GC treated with nivolumab monotherapy as a third-line or later regimen. Patients treated with nivolumab as a third-line or later therapy for unresectable or recurrent GC at Gifu University Hospital (Gifu, Japan) from April 2017 to December 2021 were included. Pretreatment data and those obtained every 2 weeks after the treatment commenced were evaluated. The association between all NLR values and disease progression for each patient was evaluated using a time-dependent Cox proportional hazards model and restricted cubic spline (RCS) curves. The study included 44 patients (23 men and 21 women). The response and disease control rates were 6.8 and 27.3%, respectively. The median PFS and OS of all patients were 1.84 months [95% confidence interval (CI), 1.32-2.14] and 5.93 months (95% CI, 3.75-10.75), respectively. The risk for progressive disease (PD) increased with higher NLR (hazard ratio, 2.25; 95% CI, 1.3-3.87). The RCS curves also indicated that the higher the NLR, the higher the risk for PD, especially if the NLR value was <3.0. NLR during treatment could predict the risk of PD, suggesting that NLR could be integrated with tumor markers, computed tomographic images and other modalities to enable treatment selection without delay.

接受 nivolumab 治疗的不可切除或复发性胃癌患者的中性粒细胞与淋巴细胞比率与疾病进展风险。
有研究表明,中性粒细胞与淋巴细胞比值(NLR)与胃癌(GC)患者的总生存期(OS)和无进展生存期(PFS)有关。本研究旨在探讨作为三线或三线以上治疗方案接受 nivolumab 单药治疗的不可切除或复发性 GC 患者在治疗期间 NLR 的动态变化与疾病进展之间的关系。纳入了2017年4月至2021年12月在岐阜大学医院(日本岐阜县)接受nivolumab作为三线或更高治疗方案治疗的不可切除或复发性GC患者。对治疗前数据和治疗开始后每两周获得的数据进行了评估。使用时间依赖性 Cox 比例危险模型和受限立方样条曲线(RCS)评估了每位患者的所有 NLR 值与疾病进展之间的关联。研究共纳入 44 名患者(23 名男性和 21 名女性)。应答率和疾病控制率分别为 6.8% 和 27.3%。所有患者的中位 PFS 和 OS 分别为 1.84 个月 [95% 置信区间 (CI),1.32-2.14] 和 5.93 个月 (95% CI,3.75-10.75)。进展性疾病(PD)的风险随着 NLR 的升高而增加(危险比为 2.25;95% CI 为 1.3-3.87)。RCS 曲线还表明,NLR 越高,进展性疾病的风险越高,尤其是当 NLR 值为
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Letters
Oncology Letters ONCOLOGY-
CiteScore
5.70
自引率
0.00%
发文量
412
审稿时长
2.0 months
期刊介绍: Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease. The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信